CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is 38%, higher than 95% of its Biotechnology peers (median -21.7%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
528.93MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-34.87%vs all stocks
Market Capitalization
528.93MUSDvs all stocks (USD)
Enterprise Value
281.33MUSDvs all stocks (USD)
Forward P/E
-1.61xvs Biotechnology peers
Price to Book (MRQ)
0.9782xvs Biotechnology peers
Enterprise to EBITDA
-0.9070xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-56.10%vs Biotechnology peers
Return on Equity (TTM)
37.96%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-310.08MUSDvs all stocks (USD)
Net Income (TTM)
-342.06MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-223.80MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-333.64MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-338.94MUSDvs all stocks (USD)
Pre-tax Income
-324.25MUSDFY2025 · Dec 31, 2025Net Income
-324.25MUSDFY2025 · Dec 31, 2025EBIT
-323.41MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-299.24MUSDFY2025 · Dec 31, 2025Research & Development
250.32MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
88.63MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
15.57MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
837.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-324.25MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
9.40MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-221.19MUSDFY2025 · Dec 31, 2025Free Cash Flow
-267.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
113.07MUSDFY2025 · Dec 31, 2025Interest Paid
889.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-324.25MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
24.18MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.04MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-5.54MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-3.81MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
70.20MUSDFY2025 · Dec 31, 2025Capital Expenditures
-46.74MUSDFY2025 · Dec 31, 2025Purchase of Investments
-444.10MUSDFY2025 · Dec 31, 2025Sale of Investments
309.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-181.34MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
352.05MUSDFY2025 · Dec 31, 2025Shares Outstanding
54.14MSharesUpdated Jul 18, 2026Float Shares
29.84MSharesUpdated Jul 18, 2026Shares Short
4.63MSharesUpdated Jul 18, 2026Short Ratio
11.42daysvs all stocks
Short % of Shares Outstanding
11.37%vs all stocks
% Held by Insiders
17.39%vs all stocks
% Held by Institutions
64.52%vs all stocks
Total Cash (MRQ)
512.18MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.46USDUpdated Jul 18, 2026Total Debt (MRQ)
254.83MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.4628xvs Biotechnology peers
Current Ratio (MRQ)
11.75xvs Biotechnology peers
Book Value per Share (MRQ)
10.17USDUpdated Jul 18, 2026Total Assets
594.73MUSDvs all stocks (USD)
Total Current Assets
348.92MUSDFY2025 · Dec 31, 2025Total Liabilities
1.47BUSDFY2025 · Dec 31, 2025Total Non-current Assets
245.82MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.42BUSDFY2025 · Dec 31, 2025Total Current Liabilities
55.01MUSDFY2025 · Dec 31, 2025Cash
19.94MUSDFY2025 · Dec 31, 2025Cash Equivalents
84.96MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
104.90MUSDFY2025 · Dec 31, 2025Other Short-term Investments
231.07MUSDFY2025 · Dec 31, 2025Accounts Payable
681.00KUSDFY2025 · Dec 31, 2025Short-term Debt
10.03MUSDFY2025 · Dec 31, 2025Other Current Liabilities
35.00KUSDFY2025 · Dec 31, 2025Long-term Debt
247.29MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
10.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-920.51MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-879.03MUSDvs all stocks (USD)
52-Week Low
7.90USDUpdated Jul 18, 202652-Week High
17.40USDUpdated Jul 18, 202652-Week Change
-34.87%vs all stocks
50-Day MA
10.46USDUpdated Jul 18, 2026200-Day MA
11.37USDUpdated Jul 18, 2026Avg 10-Day Volume
380.91KSharesUpdated Jul 18, 2026Avg 30-Day Volume
417.98KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-6.39USDUpdated Jul 18, 2026Other Income / Expense
-32.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 38%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 0.38Industry median: -0.22Industry P95: 0.23Peers compared: 261
Price-to-book is 0.98×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.98Industry median: 2.97Industry P5: 1.03Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Levered free cash flow is -$333.64M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -333,644,000Global P5: -219,013,500
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Bioperfectus Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Miracure Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai General Healthy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule